What Catalent's move into Ori's partner network covers, and what the release leaves open
Catalent's Princeton site is set to become a Center of Excellence for Ori's IRO platform, focused on autologous process development and GMP manufacturing.
The release names no clients, no go-live date and no capacity figure.
Ori Biotech announced on October 6 that Catalent joined its Preferred Partner Network. Ori's CEO says working with CDMOs helps developers shorten time to clinic and reduce comparability risk. The performance claims are Ori's own, and the release includes no supporting figures.
What was announced
Ori Biotech announced on October 6, 2026 that Catalent has joined its Preferred Partner Network. As a member, Catalent’s Princeton, New Jersey facility will become a new Center of Excellence for the IRO platform. It will support autologous cell therapy process development and GMP manufacturing for Catalent’s clients.
Fierce Pharma describes the network as a combination of academic medical centers and CDMOs that integrate IRO into their development and manufacturing. In its framing, Catalent brings scale and reach in exchange for the technology.
The announcement, in short
- Parties: Oribiotech Ltd. (Ori) announced that Catalent has joined its Preferred Partner Network (PPN).
- Site: Catalent’s Princeton, New Jersey facility will become a new Center of Excellence for the IRO platform.
- Scope: autologous cell therapy process development and GMP manufacturing for Catalent’s clients.
- Access: preferred access to Ori innovations, including the IRO platform.
- Designation: Ori says IRO has received the FDA’s Advanced Manufacturing Technology (AMT) designation.
What Ori says IRO does
Ori says IRO has demonstrated the ability to increase throughput, reduce cost of goods and accelerate development timelines. The release says it integrates with other upstream and downstream technologies to provide a streamlined, closed workflow. No figures accompany these claims in the release.
Fierce Pharma reports that the devices are a little bigger than a microwave oven and can be stacked to scale production. It describes the platform as a combination of patented hardware, software and data analytics.
Ori’s CEO, Jason C. Foster, says partnering with CDMOs like Catalent helps developers access flexible technology to shorten time to clinic and reduce comparability risk. The release gives no data behind it.
Catalent’s Princeton site is set to become an IRO Center of Excellence for autologous process development and GMP manufacturing.
What the release leaves out
The release does not name any client or program that will use the Princeton site. It gives no go-live date, no capacity figure and no commercial terms for the network membership.
The announcement follows Ori’s recent collaboration to integrate IRO into a commercially available autologous cell therapy, valued at up to $120M over 10 years. Fierce Pharma reports that the partner is an unnamed biopharma.
Catalent also launched a separate accelerated gene-to-drug-substance program for complex biologics, such as bispecific and multispecific antibodies. It is a different offering from the Ori partnership and is not part of this announcement.
What this means for a CGT program
GTC analysis: for an autologous program, comparability is where this announcement matters most. Ori describes IRO as moving a product from R&D to GMP on one platform, and its CEO ties the CDMO network to comparability risk. A sponsor should ask what comparability data exists for a process moved between PPN sites, because the release offers none.
GTC analysis: on vendor dependence, a sponsor that picks this site is also picking the IRO platform. A process built on a closed, automated system can become tied to that system, so the diligence questions are about site capacity, slot timing and tech transfer terms.
GTC analysis: on timeline, the faster-development claim is Ori’s and unquantified in the release. Until a go-live date and capacity for Princeton are published, a sponsor has nothing firm to plan around.
If you have run autologous process development or a CDMO tech transfer, GTC's Expert Network matches CMC experts like you to paid consulting work: join free.
Frequently asked questions
What did Ori Biotech and Catalent announce?
On October 6, 2026, Oribiotech Ltd. announced that Catalent has joined its Preferred Partner Network. Catalent's Princeton, New Jersey facility will become a new Center of Excellence for the IRO platform. It will support autologous cell therapy process development and GMP manufacturing for Catalent's clients.
What is Ori's Preferred Partner Network?
Fierce Pharma describes it as a combination of academic medical centers and CDMOs that integrate Ori's IRO platform into their development and manufacturing. Ori says it will continue to expand the network globally, with service partners in the U.S. and internationally. As a member, Catalent gains preferred access to Ori innovations, including IRO.
What does Ori claim the IRO platform does?
Ori says IRO has demonstrated the ability to increase throughput, reduce cost of goods and accelerate development timelines. It says the platform integrates with other upstream and downstream technologies to provide a streamlined, closed workflow. The release does not include figures for these claims.
Has the FDA approved the IRO platform?
The release says IRO has received the FDA's Advanced Manufacturing Technology (AMT) designation. It describes a designation and does not describe an approval. The release does not give a date for the designation.
Is this the same as Catalent's gene-to-drug-substance program?
No. Fierce Pharma reports that Catalent separately launched an accelerated gene-to-drug-substance program for complex biologics, such as bispecific and multispecific antibodies, shortly before the Ori announcement. It is a separate offering from the Ori partnership.
Sources
- Catalent Joins Ori Biotech’s Preferred Partner Network to Accelerate Adoption of Advanced Manufacturing Technologies - Catalent, news release, October 6, 2026.
- Catalent wins access to Iro and launches next-gen development platform - Fierce Pharma, Donavyn Coffey, October 7, 2026.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients — join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy — for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.